News Conference News ESOC 2023 ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy Todd Neale May 25, 2023
News Conference News ESOC 2023 ELAN: Early DOACs Safe, May Help After Ischemic Stroke in AF Patients Todd Neale May 24, 2023
News Conference News EuroPCR 2023 ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure Todd Neale May 18, 2023
News Daily News Generic Dabigatran Lots Pulled for Nitrosamine Impurity Michael O'Riordan March 28, 2023
News Daily News LAAO Tops Oral Anticoagulation for AF in Women and Men: Medicare Analysis Todd Neale February 24, 2023
News Daily News Left Atrial Dysfunction Tied to Cerebral Infarcts in Absence of Prior AF, Stroke Todd Neale December 21, 2022
News Daily News OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer L.A. McKeown December 16, 2022
News Daily News Slight Risk of Interstitial Lung Disease Seen With Certain DOACs Todd Neale November 23, 2022
News Daily News Apixaban Again Linked to Less Bleeding in AF Patients Michael O'Riordan October 31, 2022
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for September 2022 Shelley Wood October 03, 2022
News Daily News Another DOAC Fails in the Setting of Mechanical Heart Valves Todd Neale September 28, 2022
News Daily News Initiative Lowers Unnecessary Aspirin Use in Warfarin Users Todd Neale September 26, 2022
Presentation TCT 2022 Anticoagulation for PE: When to Switch to DOACs? Presenter: Behnood Bikdeli September 19, 2022
Presentation TCT 2022 Anticoagulation Strategies in High-Risk PE: Are DOACs Enough? When Do We Switch? Presenter: Teresa Carman September 19, 2022
Presentation TCT 2022 LAAO vs DOACs: Ongoing Trials and My Prediction Presenter: Chad Rammohan September 18, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2022 Shelley Wood September 01, 2022
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022